345 related articles for article (PubMed ID: 12015594)
21. Glycosaminoglycans inhibit neurodegenerative effects of serum amyloid P component in vitro.
Urbányi Z; Forrai E; Sárvári M; Likó I; Illés J; Pázmány T
Neurochem Int; 2005 May; 46(6):471-7. PubMed ID: 15769549
[TBL] [Abstract][Full Text] [Related]
22. Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses.
Ashton AW; Boehm MK; Gallimore JR; Pepys MB; Perkins SJ
J Mol Biol; 1997 Sep; 272(3):408-22. PubMed ID: 9325100
[TBL] [Abstract][Full Text] [Related]
23. [Amyloid P components in normal human skin and skin with lesions].
Hintner H; Breathnach SM
Hautarzt; 1988 Nov; 39(11):712-6. PubMed ID: 3072321
[TBL] [Abstract][Full Text] [Related]
24. Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC).
Kolstoe SE; Jenvey MC; Purvis A; Light ME; Thompson D; Hughes P; Pepys MB; Wood SP
Acta Crystallogr D Biol Crystallogr; 2014 Aug; 70(Pt 8):2232-40. PubMed ID: 25084341
[TBL] [Abstract][Full Text] [Related]
25. Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages.
Bijl M; Horst G; Bijzet J; Bootsma H; Limburg PC; Kallenberg CG
Arthritis Rheum; 2003 Jan; 48(1):248-54. PubMed ID: 12528126
[TBL] [Abstract][Full Text] [Related]
26. Evidence for an extended interacting surface between beta-amyloid and serum amyloid P component.
Likó I; Mák M; Klement E; Hunyadi-Gulyás E; Pázmány T; Medzihradszky KF; Urbányi Z
Neurosci Lett; 2007 Jan; 412(1):51-5. PubMed ID: 17141957
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical identification of amyloid, using an anti-human serum amyloid P component (SAP) antibody, is possible in ruminants but not in dogs and cats.
Hartig W; Leifsson PS; Nielsen OL
J Vet Med A Physiol Pathol Clin Med; 2005 Nov; 52(9):447-53. PubMed ID: 16268955
[TBL] [Abstract][Full Text] [Related]
28. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.
Jager PL; Hazenberg BP; Franssen EJ; Limburg PC; van Rijswijk MH; Piers DA
J Nucl Med; 1998 Apr; 39(4):699-706. PubMed ID: 9544684
[TBL] [Abstract][Full Text] [Related]
29. Studies of the structure and binding properties of hamster female protein.
Tennent GA; Baltz ML; Osborn GD; Butler PJ; Noble GE; Hawkins PN; Pepys MB
Immunology; 1993 Dec; 80(4):645-51. PubMed ID: 7508422
[TBL] [Abstract][Full Text] [Related]
30. Immunoradiometric assay for human serum amyloid P component.
Millar DJ; Hutchinson WL; Pepys MB
J Immunol Methods; 2011 Aug; 371(1-2):18-24. PubMed ID: 21708157
[TBL] [Abstract][Full Text] [Related]
31. Formation of experimental murine AA amyloid fibrils in SAP-deficient mice: high resolution ultrastructural study.
Inoue S; Kawano H; Ishihara T; Maeda S; Ohno S
Amyloid; 2005 Sep; 12(3):157-63. PubMed ID: 16194870
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
33. Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis.
Sahota T; Berges A; Barton S; Cookson L; Zamuner S; Richards D
CPT Pharmacometrics Syst Pharmacol; 2015 Feb; 4(2):e15. PubMed ID: 26225229
[TBL] [Abstract][Full Text] [Related]
34. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis.
Hawkins PN; Wootton R; Pepys MB
J Clin Invest; 1990 Dec; 86(6):1862-9. PubMed ID: 2254450
[TBL] [Abstract][Full Text] [Related]
35. Colocalization of apolipoprotein AI in various kinds of systemic amyloidosis.
Sakata N; Hoshii Y; Nakamura T; Kiyama M; Arai H; Omoto M; Morimatsu M; Ishihara T
J Histochem Cytochem; 2005 Feb; 53(2):237-42. PubMed ID: 15684336
[TBL] [Abstract][Full Text] [Related]
36. C-reactive protein and SAP-like pentraxin are both present in Limulus polyphemus haemolymph: crystal structure of Limulus SAP.
Shrive AK; Metcalfe AM; Cartwright JR; Greenhough TJ
J Mol Biol; 1999 Jul; 290(5):997-1008. PubMed ID: 10438598
[TBL] [Abstract][Full Text] [Related]
37. Investigating interactions of the pentraxins serum amyloid P component and C-reactive protein by mass spectrometry.
Aquilina JA; Robinson CV
Biochem J; 2003 Oct; 375(Pt 2):323-8. PubMed ID: 12892563
[TBL] [Abstract][Full Text] [Related]
38. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.
Bodin K; Ellmerich S; Kahan MC; Tennent GA; Loesch A; Gilbertson JA; Hutchinson WL; Mangione PP; Gallimore JR; Millar DJ; Minogue S; Dhillon AP; Taylor GW; Bradwell AR; Petrie A; Gillmore JD; Bellotti V; Botto M; Hawkins PN; Pepys MB
Nature; 2010 Nov; 468(7320):93-7. PubMed ID: 20962779
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
Wechalekar A; Antoni G; Al Azzam W; Bergström M; Biswas S; Chen C; Cheriyan J; Cleveland M; Cookson L; Galette P; Janiczek RL; Kwong RY; Lukas MA; Millns H; Richards D; Schneider I; Solomon SD; Sörensen J; Storey J; Thompson D; van Dongen G; Vugts DJ; Wall A; Wikström G; Falk RH
BMC Cardiovasc Disord; 2022 Feb; 22(1):49. PubMed ID: 35152886
[TBL] [Abstract][Full Text] [Related]
40. Targeted treatment for amyloidosis.
Pepys-Vered ME; Pepys MB
Isr Med Assoc J; 2014 May; 16(5):277-80. PubMed ID: 24979830
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
